{
    "clinical_study": {
        "@rank": "63949", 
        "arm_group": {
            "arm_group_label": "Combination therapy- bicalutamide and finasteride", 
            "arm_group_type": "Experimental", 
            "description": "3-month (90-day) course of bicalutamide 50 mg by mouth daily and finasteride 5 mg by mouth daily"
        }, 
        "brief_summary": {
            "textblock": "This is an open label, single site, single arm Phase II study to evaluate the combination of\n      bicalutamide plus finasteride in men with MRI detectable significant prostate nodules\n      followed on active surveillance."
        }, 
        "brief_title": "A Phase 2 Study of Bicalutamide Plus Finasteride in Men With MRI Detectable Prostate Nodules Undergoing Active Surveillance", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Detectable Prostate Nodules", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This research is being done to determine the negative re-biopsy rate as determined by\n      MRI/TRUS fusion guided biopsy targeting the dominant nodule site defined by pre-treatment\n      MRI following three months (90 days) of combination bicalutamide plus finasteride."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Willing and able to provide written informed consent.\n\n          2. Age \u2265 18 years\n\n          3. Eastern cooperative group (ECOG) performance status \u22642\n\n          4. Documented histologically confirmed adenocarcinoma of the prostate (minimum 12 core\n             prostate biopsy completed within 90 days of screening)\n\n          5. Very low-risk prostate cancer as defined by:\n\n               -  Gleason score \u2264 6\n\n               -  PSA density \u2264 0.15 ng/mL/mL\n\n               -  PSA < 10 ng/mL\n\n               -  Clinical tumor stage T1 (cT1) (i.e., no palpable nodule by digital rectal exam)\n\n               -  \u22642 prostate cores positive for prostatic adenocarcinoma\n\n               -  \u226450% of any given core involved by prostatic adenocarcinoma\n\n          6. Willing and qualified for active surveillance at Johns Hopkins\n\n          7. Presence of at least one MRI significant visible prostate tumor (i.e., \u22655 mm in at\n             least one dimension) that has been biopsy proven to be prostatic adenocarcinoma Note:\n             MRI may occur pre- or post-prostate biopsy. If done post-biopsy, the MRI must not\n             occur <8 weeks post-prostate biopsy.\n\n          8. Serum testosterone \u2265150 ng/dL\n\n          9. Able to swallow the study drugs whole as a tablet\n\n        Exclusion Criteria:\n\n          1. Prior local therapy to treat prostate cancer (e.g., radical prostatectomy, radiation\n             therapy, brachytherapy)\n\n          2. Prior use of bicalutamide\n\n          3. Prior use of finasteride within the past year\n\n          4. Prior or ongoing systemic therapy for prostate cancer including, but not limited to:\n\n               -  Hormonal therapy (e.g., leuprolide, goserelin, triptorelin)\n\n               -  CYP-17 inhibitors (e.g., abiraterone, ketoconazole)\n\n               -  Antiandrogens (e.g., bicalutamide, flutamide, nilutamide)\n\n               -  Second generation antiandrogens (e.g., enzalutamide, ARN-509)\n\n               -  Immunotherapy (e.g., sipuleucel-T, ipilimumab)\n\n               -  Chemotherapy (e.g., docetaxel, cabazitaxel)\n\n          5. Evidence of serious and/or unstable pre-existing medical, psychiatric or other\n             condition (including laboratory abnormalities) that could interfere with patient\n             safety or provision of informed consent to participate in this study.\n\n          6. Any psychological, familial, sociological, or geographical condition that could\n             potentially interfere with compliance with the study protocol and follow-up schedule.\n\n          7. Abnormal bone marrow function [absolute neutrophil count (ANC)<1500/mm3, platelet\n             count <100,000/mm3, hemoglobin <9 g/dL]\n\n          8. Abnormal liver function (bilirubin, AST, ALT \u2265 3 x upper limit of normal)\n\n          9. Abnormal kidney function (serum creatinine \u2265 2 x upper limit of normal)\n\n         10. Abnormal cardiac function as manifested by NYHA (New York Heart Association) class\n             III or IV heart failure or history of a prior myocardial infarction (MI) within the\n             last five years prior to enrollment in the study."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "29", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02146937", 
            "org_study_id": "J1408", 
            "secondary_id": "NA_00092522"
        }, 
        "intervention": {
            "arm_group_label": "Combination therapy- bicalutamide and finasteride", 
            "description": "3-month (90-day) course of bicalutamide 50 mg by mouth daily and finasteride 5 mg by mouth daily", 
            "intervention_name": "Bicalutamide plus Finasteride- Combination therapy", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Finasteride", 
                "Bicalutamide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "active surveillance", 
            "MRI/transrectal ultrasound fusion guided biopsy", 
            "biopsy"
        ], 
        "lastchanged_date": "May 23, 2014", 
        "location": {
            "contact": {
                "email": "cchapma7@jhmi.edu", 
                "last_name": "Carolyn Chapman, RN", 
                "phone": "443-287-7841"
            }, 
            "contact_backup": {
                "email": "lsmithw1@jhmi.edu", 
                "last_name": "Linnea Smith-Waters, BS,CCRP", 
                "phone": "410-502-0017"
            }, 
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21205"
                }, 
                "name": "Johns Hopkins Hospital"
            }, 
            "investigator": {
                "last_name": "Kenneth Pienta, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2 Study of Bicalutamide Plus Finasteride in Men With MRI Detectable Prostate Nodules Undergoing Active Surveillance", 
        "other_outcome": [
            {
                "measure": "Overall rate of exit at 2 years from the active surveillance program at Johns Hopkins following treatment with bicalutamide plus finasteride.", 
                "safety_issue": "No", 
                "time_frame": "two years"
            }, 
            {
                "measure": "Rate of local treatment (e.g., radical prostatectomy, radiation therapy, brachytherapy) at 2 years and the local treatment free survival", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "overall_contact": {
            "email": "lsmithw1@jhmi.edu", 
            "last_name": "Linnea M Smith-Waters, BS, CCRP", 
            "phone": "410-502-0017"
        }, 
        "overall_contact_backup": {
            "email": "cchapma7@jhmi.edu", 
            "last_name": "Carolyn Chapman, RN", 
            "phone": "443-287-7841"
        }, 
        "overall_official": {
            "affiliation": "Johns Hopkins University", 
            "last_name": "Kenneth Pienta, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine the negative re-biopsy rate as determined by MRI/TRUS fusion guided biopsy targeting the dominant nodule site defined by pre-treatment MRI following three months (90 days) of combination bicalutamide plus finasteride.", 
            "measure": "Negative re-biopsy rate", 
            "safety_issue": "No", 
            "time_frame": "three months (90 days)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02146937"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Rate of exit at 2 years from the active surveillance program at Johns Hopkins due to pathologic upstaging following treatment with bicalutamide plus finasteride.", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "PSA progression rates and PSA progression free survival (PFS), as defined by the Prostate Cancer Working Group 2 (PCWG2) criteria, at 2 years [Scher et al, 2008].", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Rate of radiographic disappearance of MRI detectable prostate cancer following treatment with combination bicalutamide plus finasteride (i.e., decrease in size of the target prostate cancer nodule below 5 mm).", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Adverse events as assessed by the revised National Cancer Institute Common Toxicity Criteria (NCI CTC), version 4.0 published 14 June 2010.", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "measure": "Quality of life utilizing the FACT-P and SF36 surveys", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Sidney Kimmel Comprehensive Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sidney Kimmel Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}